Inspire Medical's Q3 Net Income Halves Amid Soaring SG&A Costs

Ticker: INSP · Form: 10-Q · Filed: Nov 3, 2025 · CIK: 1609550

Inspire Medical Systems, INC. 10-Q Filing Summary
FieldDetail
CompanyInspire Medical Systems, INC. (INSP)
Form Type10-Q
Filed DateNov 3, 2025
Risk Levelmedium
Pages16
Reading Time19 min
Key Dollar Amounts$0.001
Sentimentbearish

Sentiment: bearish

Topics: Medical Devices, Sleep Apnea, Earnings Decline, SG&A Expenses, Cash Flow, Share Repurchase, Profitability

Related Tickers: INSP, RMD, PHG

TL;DR

**INSP's revenue growth is overshadowed by plummeting net income and ballooning SG&A, making it a risky bet despite market expansion.**

AI Summary

Inspire Medical Systems, Inc. (INSP) reported revenue of $224.5 million for the three months ended September 30, 2025, an increase from $203.2 million in the same period of 2024. Net income, however, decreased to $9.9 million for the quarter, down from $18.5 million in Q3 2024. For the nine months ended September 30, 2025, revenue grew to $642.9 million from $563.1 million year-over-year, but net income also saw a decline to $9.3 million from $18.3 million. The company experienced a significant increase in selling, general and administrative expenses, rising to $158.9 million for the quarter from $130.4 million in Q3 2024, and to $462.7 million for the nine-month period from $388.1 million. Research and development expenses slightly decreased to $24.2 million for the quarter from $26.1 million. Cash and cash equivalents decreased by $37.3 million to $112.8 million as of September 30, 2025, from $150.2 million at the beginning of the period, partly due to $125.0 million in share repurchases. Inventories increased substantially to $141.8 million from $80.1 million at December 31, 2024, indicating potential inventory management challenges or strategic build-up.

Why It Matters

Inspire Medical Systems' declining net income despite revenue growth signals potential margin pressures and operational inefficiencies, which could concern investors. The substantial increase in selling, general and administrative expenses, up 21.8% quarter-over-quarter, suggests aggressive market expansion or rising overheads that are eating into profitability. For employees, continued growth in revenue could imply job security, but a squeeze on net income might impact future compensation or investment in new initiatives. Customers may benefit from increased market presence, but the company's ability to sustain innovation against competitors like ResMed or Philips could be hampered if profitability trends continue downwards. The broader market will watch if INSP can effectively scale its operations without sacrificing the bottom line, setting a precedent for other high-growth medical technology firms.

Risk Assessment

Risk Level: medium — The risk level is medium due to a significant decline in net income from $18.5 million in Q3 2024 to $9.9 million in Q3 2025, despite revenue growth. This is primarily driven by a substantial increase in selling, general and administrative expenses, which rose by $28.5 million to $158.9 million for the quarter. Additionally, cash and cash equivalents decreased by $37.3 million, partly due to $125.0 million in share repurchases, indicating a reduction in liquidity.

Analyst Insight

Investors should closely monitor Inspire Medical Systems' upcoming earnings calls for management's strategy to control SG&A expenses and improve net income margins. Consider holding off on new investments until there's clear evidence of expense management and a reversal in the net income trend, as current profitability challenges outweigh revenue growth.

Financial Highlights

revenue
$224.5M
operating Margin
4.3%
total Assets
$807.7M
total Debt
$141.3M
net Income
$9.9M
eps
$0.34
gross Margin
85.8%
cash Position
$112.8M
revenue Growth
+10.5%

Key Numbers

Key Players & Entities

FAQ

Why did Inspire Medical Systems' net income decrease in Q3 2025?

Inspire Medical Systems' net income decreased to $9.9 million in Q3 2025 from $18.5 million in Q3 2024 primarily due to a significant increase in selling, general and administrative expenses, which rose by $28.5 million to $158.9 million.

What were Inspire Medical Systems' revenues for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Inspire Medical Systems reported revenues of $642.9 million, an increase from $563.1 million in the same period of 2024.

How much did Inspire Medical Systems spend on share repurchases?

Inspire Medical Systems spent $125.0 million on share repurchases of common stock during the nine months ended September 30, 2025.

What is the current cash position of Inspire Medical Systems?

As of September 30, 2025, Inspire Medical Systems had cash and cash equivalents of $112.8 million, down from $150.2 million at December 31, 2024.

What is Inspire Medical Systems' primary business?

Inspire Medical Systems, Inc. is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA) using its proprietary Inspire system.

How have Inspire Medical Systems' operating expenses changed?

Total operating expenses for Inspire Medical Systems increased to $183.1 million for the three months ended September 30, 2025, from $156.5 million in the prior year, driven mainly by higher selling, general and administrative costs.

What are the key risks highlighted in Inspire Medical Systems' 10-Q?

Key risks include a history of operating losses, dependency on the Inspire system for revenues, ability to achieve and maintain adequate reimbursement levels, competitive pressures, and the ability to manage growth and supply chain disruptions.

Has Inspire Medical Systems expanded its product indications?

The filing mentions the company's ability to expand its indications and develop and commercialize additional products and enhancements to its Inspire system as a forward-looking statement and a risk factor, but does not detail specific recent expansions.

What was the change in Inspire Medical Systems' inventory levels?

Inspire Medical Systems' inventories, net, increased significantly to $141.8 million as of September 30, 2025, from $80.1 million at December 31, 2024.

When did Inspire therapy receive FDA approval?

Inspire therapy received premarket approval from the FDA in 2014 and has been commercially available in certain European markets since 2011 and certain Asia Pacific markets since 2021.

Risk Factors

Industry Context

Inspire Medical Systems operates in the rapidly evolving medical technology sector, specifically addressing the large and growing market for sleep apnea treatment. The company's neurostimulation approach offers a unique alternative to traditional CPAP machines. Key industry trends include increasing adoption of minimally invasive procedures, demand for innovative chronic disease management solutions, and a competitive landscape with established players and emerging technologies.

Regulatory Implications

The company's reliance on FDA, EU MDR, and other international regulatory bodies for product approval and market access presents ongoing risks. Changes in regulatory requirements, post-market surveillance, or potential recalls could significantly impact operations and financial performance. Compliance with evolving medical device regulations is paramount for continued market access and growth.

What Investors Should Do

  1. Monitor SG&A Expense Growth
  2. Analyze Inventory Levels
  3. Evaluate Profitability Trends
  4. Assess Cash Burn and Share Repurchases

Key Dates

Glossary

Obstructive Sleep Apnea (OSA)
A sleep disorder in which breathing repeatedly stops and starts during sleep due to the airway becoming blocked. (This is the primary condition treated by Inspire Medical Systems' core product.)
Neurostimulation Technology
A medical treatment that uses electrical impulses to stimulate nerves. (This is the underlying technology of the Inspire system, targeting the hypoglossal nerve to treat OSA.)
Premarket Approval (PMA)
The FDA process of granting approval to manufacturers of certain medical devices to market their product in the United States. (The company has obtained PMA for its Inspire system, a critical regulatory step.)
Accumulated Deficit
The total net losses of a company that have not been offset by net income since its inception. (Inspire Medical Systems currently has an accumulated deficit of $282.6 million, indicating it has historically incurred more expenses than revenues.)
Available-for-Sale Investments
Investments that are not classified as held-to-maturity or trading securities, typically reported at fair value with unrealized gains/losses in other comprehensive income. (The company holds significant investments classified as available-for-sale, which are subject to market fluctuations.)

Year-Over-Year Comparison

Compared to the prior year, Inspire Medical Systems has demonstrated robust revenue growth, with Q3 revenue increasing by 10.5% to $224.5 million and nine-month revenue up by 14.2% to $642.9 million. However, profitability has deteriorated significantly, with net income for Q3 falling by 46.4% to $9.9 million. This decline is largely attributable to a substantial 21.8% increase in Selling, General, and Administrative expenses, which outpaced revenue growth. While R&D expenses saw a slight decrease, the overall operating expense structure has become less efficient. New risks related to inventory build-up and a reduced cash position are also apparent.

Filing Stats: 4,652 words · 19 min read · ~16 pages · Grade level 16.3 · Accepted 2025-11-03 16:07:50

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements 3 PART I. FINANCIAL INFORMATION 5 Item 1.

Financial Statements

Financial Statements 5 Balance Sheets 5 6 7 9

Notes to Financial Statements

Notes to Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 40 Item 4.

Controls and Procedures

Controls and Procedures 41 PART II. OTHER INFORMATION 41 Item 1.

Legal Proceedings

Legal Proceedings 41 Item 1A.

Risk Factors

Risk Factors 41 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 43 Item 3. Defaults Upon Senior Securities 43 Item 4. Mine Safety Disclosures 43 Item 5. Other Information 43 Item 6. Exhibits 45

Signatures

Signatures 46 2 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the "Quarterly Report") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact contained in this Quarterly Report are forward-looking statements, including, without limitation, statements regarding our future results of operations and financial position, business strategy, the impact of macroeconomic trends on our business, financial results and financial position, prospective products, international product approvals and commercializations, our expectations regarding reimbursement levels for Inspire therapy procedures, research and development costs, timing and likelihood of success, other insurance providers' plans to begin covering our Inspire therapy, our sales and marketing initiatives, potential supply chain disruptions, and the plans and objectives of management for future operations. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "can," "continue," "could," "designed," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "target," "will," "would," or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this Quarterly Report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Inspire Medical Systems, Inc. Consolidated Balance Sheets (in thousands, except share and per share amounts) September 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 112,845 $ 150,150 Investments, short-term 209,747 295,396 Accounts receivable, net of allowance for credit losses of $ 1,098 and $ 880 , respectively 107,989 93,068 Inventories, net 141,777 80,118 Prepaid expenses and other current assets 14,131 12,074 Total current assets 586,489 630,806 Investments, long-term 88,353 70,995 Property and equipment, net 91,506 71,925 Operating lease right-of-use assets 24,070 23,314 Other non-current assets 17,298 11,343 Total assets $ 807,716 $ 808,383 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 59,240 $ 38,687 Accrued expenses 51,603 49,814 Total current liabilities 110,843 88,501 Operating lease liabilities, non-current portion 30,302 30,039 Other non-current liabilities 111 148 Total liabilities 141,256 118,688 Stockholders' equity: Preferred Stock, $ 0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding — — Common Stock, $ 0.001 par value per share; 200,000,000 shares authorized; 29,053,367 and 29,740,176 issued and outstanding at September 30, 2025 and December 31, 2024, respectively 29 30 Additional paid-in capital 948,374 981,043 Accumulated other comprehensive income 639 536 Accumulated deficit ( 282,582 ) ( 291,914 ) Total stockholders' equity 666,460 689,695 Total liabilities and stockholders' equity $ 807,716 $ 808,383 The accompanying notes are an integral part of these unaudited consolidated financial statements. 5 Table of Contents Inspire Medical Systems, Inc. Consolidated Statements of Operations and Comprehensive Income (unaudited) (in thousands, except share and per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Rev

Notes to Consolidated Financial Statements (Unaudited)

Notes to Consolidated Financial Statements (Unaudited) (Table amounts in thousands, except share and per share amounts) 1. Organization Description of Business Inspire Medical Systems, Inc. is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). Our proprietary Inspire system is the first and only United States ("U.S.") Food and Drug Administration ("FDA"), European Union ("EU"), Medical Devices Regulation, and Japan Pharmaceuticals and Medical Devices Agency-approved neurostimulation technology of its kind that provides a safe and effective treatment for patients with moderate to severe OSA. Inspire therapy received premarket approval from the FDA in 2014 and has been commercially available in certain European markets since 2011 and certain Asia Pacific markets since 2021. 2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial reporting and as required by the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, the results of operations for the interim periods are not necessarily indicative of the operating results for the full

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) (Table amounts in thousands, except share and per share amounts) million of gain, net, respectively. For the nine-month periods ended September 30, 2025 and 2024 we recognized $ 1.0 million of gain and $ 0.1 million of loss, net, respectively. Any unrealized gains and losses due to translation adjustments are included in accumulated other comprehensive income within stockholders' equity in the consolidated balance sheets. We had $ 0.0 million and $ 0.2 million of unrecognized gain in our accumulated other comprehensive income balance as of September 30, 2025 and December 31, 2024, respectively. Investments Our investments are classified as available-for-sale and consisted of the following: September 30, 2025 Amortized Unrealized Gross Aggregate Cost Gains Losses Fair Value Short-Term: Commercial paper $ 21,903 $ 24 $ — $ 21,927 Corporate debt securities 45,854 145 — 45,999 U.S. treasury debt securities 141,612 213 ( 4 ) 141,821 Short-term investments $ 209,369 $ 382 $ ( 4 ) $ 209,747 Long-Term: Corporate debt securities $ 51,977 $ 139 $ ( 10 ) $ 52,106 U.S. treasury debt securities 36,111 150 ( 14 ) 36,247 Long-term investments $ 88,088 $ 289 $ ( 24 ) $ 88,353 December 31, 2024 Amortized Unrealized Gross Aggregate Cost Gains Losses Fair Value Short-Term: Commercial paper $ 19,806 $ 25 $ — $ 19,831 Corporate debt securities 47,226 80 ( 7 ) 47,299 Certificates of deposit 7,684 10 — 7,694 U.S. treasury debt securities 220,283 346 ( 57 ) 220,572 Short-term investments $ 294,999 $ 461 $ ( 64 ) $ 295,396 Long-Term: Corporate debt securities $ 23,915 $ 59 $ ( 49 ) $ 23,925 Asset-backed securities 287 — — 287 U.S. treasury debt securities 46,818 50 ( 85 ) 46,783 Long-term investments $ 71,020 $ 109 $ ( 134 ) $ 70,995 The following table shows all available-for-sale investments in an unrealized loss position for which an allowance for credit losses has not been recorded and the relat

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) (Table amounts in thousands, except share and per share amounts) September 30, 2025 Less than 12 Months 12 Months or Greater Total Fair Value Unrealized Loss Fair Value Unrealized Loss Fair Value Unrealized Loss Corporate debt securities $ 16,455 $ ( 12 ) $ — $ — $ 16,455 $ ( 12 ) U.S. Treasury debt securities 30,000 ( 21 ) 16,003 ( 10 ) 46,003 ( 31 ) Total $ 46,455 $ ( 33 ) $ 16,003 $ ( 10 ) $ 62,458 $ ( 43 ) December 31, 2024 Less than 12 Months 12 Months or Greater Total Fair Value Unrealized Loss Fair Value Unrealized Loss Fair Value Unrealized Loss Corporate debt securities $ 11,728 $ ( 56 ) $ — $ — $ 11,728 $ ( 56 ) U.S. Treasury debt securities 69,402 ( 220 ) — — 69,402 ( 220 ) Total $ 81,130 $ ( 276 ) $ — $ — $ 81,130 $ ( 276 ) Investments are classified as available-for-sale and are reported at their estimated fair market values which are based on quoted, active or inactive market prices when available. Any unrealized gains and losses due to interest rate fluctuations and other external factors are reported as a separate component of accumulated other comprehensive income within stockholders' equity. We had $ 0.6 million and $ 0.4 million of unrecognized gain in our accumulated other comprehensive income balance at September 30, 2025 and December 31, 2024, respectively. Any realized gains and losses are calculated on the specific identification method and reported net in other expense (income), net in the consolidated statements of operations and comprehensive income. We recognized $ 0 of gross realized gains and losses from the sale or maturity of available-for-sale investments during each of the nine months ended September 30, 2025 and 2024, respectively. As of September 30, 2025 and December 31, 2024, we had no investments with a contractual maturity of greater than two years. Currently, we do not intend to sell the investments, and it is not more likely than not that we will be

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) (Table amounts in thousands, except share and per share amounts) Level 2: Inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3: Unobservable inputs that are supported by little or no market activities, which would require us to develop our own assumptions. We classify instrume

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing